Abstract: Provided is a GII.4 norovirus virus-like particle or active fragment thereof, and use thereof, the virus-like particle comprising or being composed of an amino acid sequence shown as SEQ ID NO: 4. Further, provided is a composition or a kit comprising the GII.4 norovirus virus-like particle, and use thereof. The objective of covering multiple genotypes is achieved by using a single antigen of the invention, the process difficulty of the preparation for a pharmaceutical composition or a vaccine can be reduced, and the production cost is decreased. Also, provided is a norovirus immune composition or a kit comprising GII.2, GII.4, GII.6, and GII.17 norovirus virus-like particles or active fragments thereof, and use thereof.
Type:
Application
Filed:
December 21, 2021
Publication date:
February 29, 2024
Applicant:
GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD.
Abstract: The present invention belongs to the field of biopharmaceutics and in particular relates to a pharmaceutical composition. The pharmaceutical composition comprises a hepatitis B surface antigen, a hepatitis B core antigen, and an immunostimulatory composition, wherein the immunostimulatory composition comprises a saponin and a CpG oligodeoxynucleotide, or consists of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide.
Type:
Application
Filed:
December 11, 2020
Publication date:
March 9, 2023
Applicant:
GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD.
Abstract: A pharmaceutical composition comprising: i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of them; ii) an immunostimulatory composition comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide. Use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating a varicella-zoster virus infection and/or a varicella-zoster virus mediated disease. The pharmaceutical composition achieves an unexpected technical effect and can mediate a stronger immune response.
Type:
Application
Filed:
December 11, 2020
Publication date:
March 9, 2023
Applicant:
GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD.
Abstract: Provided is an immunostimulatory composition, comprising a saponin and a CpG oligodeoxynucleotide, or consisting of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide, wherein the sequence of the CpG oligodeoxynucleotide has two or more copies of 5?-TTCGTT-3? motif or 5?-TCGTCGTCG-3? motif. Also provided is use of the immunostimulatory composition in the preparation of a medication for treating diseases.
Type:
Application
Filed:
December 11, 2020
Publication date:
February 9, 2023
Applicant:
GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD.
Abstract: The present invention discloses a pharmaceutical preparation for treating hepatitis B, a preparation method and use thereof. The pharmaceutical preparation comprises a solution of hepatitis B surface antigen, further a solution of hepatitis B core antigen, and furthermore an oligodeoxynucleotide solution. The pharmaceutical preparation is free of saccharide, has a simple composition and a good antigen stability, without the adverse reactions caused by aluminum adjuvants, and shows good preservation effects in long-term stability experiments.
Type:
Application
Filed:
November 15, 2019
Publication date:
March 24, 2022
Applicant:
GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD.